Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Shen, Jing
    • Other Affiliation: Columbia University
  • Gammon, Marilie D.
    • Affiliation: Gillings School of Global Public Health, Department of Epidemiology
  • Terry, Mary
    • Other Affiliation: Columbia University
  • Teitelbaum, Susan L
    • Other Affiliation: Mt. Sinai School of Medicine
  • Neugut, Alfred I
    • Other Affiliation: Columbia University
  • Santella, Regina M
    • Other Affiliation: Columbia University
Abstract
  • Introduction The association between use of nonsteroidal anti-inflammatory drugs (NSAIDs) and breast cancer risk remains unclear. Inconsistencies in previously reported findings may be partly due to differences in expression of cyclooxygenase (COX)-2. We hypothesized that genetic polymorphisms (COX-2 .926, COX-2 .5209, and COX-2 .8473) may reduce overall breast cancer risk or risk for subtypes of breast cancer by modulating the inflammatory response and may interact with aspirin or any NSAID use. Methods We conducted a population-based, case-control study in which we genotyped 1,067 breast cancer cases and 1,110 control individuals included in the Long Island Breast Cancer Study Project. Results No major effects of the three COX-2 variant alleles on breast cancer risk were found. A total of eight distinct haplotypes and 18 diplotypes were observed in the population. Overall, no significant associations between COX-2 haplotypes/diplotypes and breast cancer risk were observed. Among women who used aspirin or any NSAID there was little evidence for an interaction with the at-risk COX-2 genotypes, with one exception. Among women with hormone receptor positive breast cancer, the reduced risk for any NSAID use was only evident among those who had at least one variant C allele of COX-2 .8473 (odds ratio = 0.7, 95% confidence interval = 0.5 to 1.0; P for the interaction = 0.02). There was no corresponding interaction for aspirin use, possibly because of limited power. Conclusion These data provide modest evidence that the C allele of COX-2 .8473 may interact with NSAIDs to reduce risk for hormone receptor positive breast cancer.
Date of publication
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
Rights holder
  • Jing Shen et al.; licensee BioMed Central Ltd.
License
Journal title
  • Breast Cancer Research
Journal volume
  • 8
Journal issue
  • 6
Page start
  • R71
Language
  • English
Is the article or chapter peer-reviewed?
  • Yes
ISSN
  • 1465-5411
Bibliographic citation
  • Breast Cancer Research. 2006 Dec 20;8(6):R71
Publisher
  • BioMed Central Ltd
Access right
  • Open Access
Date uploaded
  • January 27, 2017

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 13058_2006_article_1593.pdf 2019-05-06 Public Download